Since the cGAS-STING pathway can promote the maintenance of stem-like central memory CD8+ T-cells and augment their differentiation by regulating the expression of transcription factor TCF1 and restricting Akt activity, respectively, STING agonists are suggested to potentiate anti-tumor responses of CAR-T-cell therapies through enhancing the production of stem-like central memory CD8+ T-cells (198). The gene discussed is STING1; the disease is neoplasm.